SUPRIYA LIFESCIENCE Q2 FY27 CONCALL: MAINTAINS ₹1,000 CR FY27 REVENUE GUIDANCE, CUTS EBITDA MARGIN OUTLOOK TO 23–25% FROM 32–35%; TARGETS 20%+ ANNUAL GROWTH OVER 3–4 YEARS, AMBARNATH ₹450–500 CR REVENUE POTENTIAL & MAJOR CDMO CONTRACT